What is Daratumumab-lenalidomide-dexamethasone (DRd)?
Category: Prescription Drugs
See also: Daratumumab Dexamethasone Lenalidomide
Daratumumab-lenalidomide-dexamethasone (Drd), also known as DRd, is a regimen that may be used for the treatment of multiple myeloma. It includes daratumumab and lenalidomide, both of which are anticancer agents, and dexamethasone, a corticosteroid.
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Multiple myeloma | 2 | 5 | |
| Myelomalacia | 1 | 3 | |
| Nonsecretory multiple myeloma | 1 | 3 |
- Major
- Moderate
- Slight
- None
- Can't tell
Side effects
Side effects as an overall problem
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 2 | |
| Moderate | 3 | |
| Mild | 0 | |
| None | 0 |
Commonly reported side effects and conditions associated with Daratumumab-lenalidomide-dexamethasone (DRd)
| Side effect | Patients | Percentage |
|---|---|---|
| Fatigue | 1 | |
| Peripheral neuropathy | 1 | |
| Redness of skin (erythema) | 1 |
Why patients stopped taking Daratumumab-lenalidomide-dexamethasone (DRd)
Multiple reasons could be selected
| Reason | Patients | Percentage |
|---|---|---|
| Side effects too severe | 1 |
Duration
Stopped taking Daratumumab-lenalidomide-dexamethasone (DRd)
| Duration | Patients | Percentage |
|---|---|---|
| 6 months - 1 year | 1 |
What people switch to and from
Patients started taking Daratumumab-lenalidomide-dexamethasone (DRd) after stopping:
| Treatment | Patients | Percentage |
|---|---|---|
| Carfilzomib (Kyprolis) | 1 |
Patients stopped taking Daratumumab-lenalidomide-dexamethasone (DRd) and switched to:
| Treatment | Patients | Percentage |
|---|---|---|
| Daratumumab (Darzalex) | 1 | |
| Dexamethasone (Decadron) | 1 |
Last updated: